Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/20075
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRoelofs, Charlotte-
dc.contributor.authorHollande, Frédéric-
dc.contributor.authorRedvers, Richard-
dc.contributor.authorAnderson, Robin L-
dc.contributor.authorMerino, Delphine-
dc.date2019-01-09-
dc.date.accessioned2019-01-18T04:19:39Z-
dc.date.available2019-01-18T04:19:39Z-
dc.date.issued2019-01-09-
dc.identifier.citationBiochemical Society transactions 2019; 47(1): 109-117-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/20075-
dc.description.abstractUntil recently, established cancer cell lines have been used extensively in breast cancer research, due largely to the difficulties associated with the manipulation and long-term maintenance in culture of primary tumour cells from patients. The recent development of organoid cultures has provided new opportunities to model and analyse patient samples, allowing the propagation of malignant cells under conditions that resemble the three-dimensional growth of breast tumours. They have proved efficacious in preserving the heterogeneity of primary samples and are emerging as a new model to further characterise the molecular features of breast cancer. Organoids formed from patient-derived cells are now in use for the evaluation of drug sensitivity and to validate disease-causing genomic variations. Here, the advantages and limitations of organoid cultures will be discussed and compared with the parallel development of other two- and three-dimensional culture strategies and with patient-derived xenografts. In particular, we will focus on the molecular characterisation of breast cancer organoids and provide some examples of how they have been used in functional studies.-
dc.language.isoeng-
dc.subjectbreast cancer-
dc.subjectdrug testing-
dc.subjectgenomics-
dc.subjectorganoids-
dc.titleBreast tumour organoids: promising models for the genomic and functional characterisation of breast cancer.-
dc.typeJournal Article-
dc.identifier.journaltitleBiochemical Society transactions-
dc.identifier.affiliationDepartment of Clinical Pathology, The University of Melbourne, Parkville, Victoria 3010, Australiaen
dc.identifier.affiliationThe Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria 3052, Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, Victoria, Australiaen
dc.identifier.affiliationDepartment of Medical Biology, The University of Melbourne, Parkville, Victoria 3010, Australiaen
dc.identifier.doi10.1042/BST20180375-
dc.identifier.orcid0000-0002-8075-6275-
dc.identifier.orcid0000-0002-6841-7422-
dc.identifier.pubmedid30626705-
dc.type.austinJournal Article-
dc.type.austinReview-
local.name.researcherAnderson, Robin L
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

34
checked on Jan 15, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.